| Drug Name |
Paliperidone palmitate |
| Drug ID |
BADD_D01657 |
| Description |
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] |
| Indications and Usage |
For the treatment of schizophrenia. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N05AX13 |
| DrugBank ID |
DB01267
|
| KEGG ID |
D05340
|
| MeSH ID |
D000068882
|
| PubChem ID |
9852746
|
| TTD Drug ID |
D0B3UJ
|
| NDC Product Code |
50458-561; 58032-1010; 65089-0047; 50458-606; 65085-0066; 64552-4063; 47848-058; 50458-560; 55111-926; 65372-1174; 50458-564; 64552-4066; 64552-4076; 68108-0630; 14501-0069; 50458-609; 50458-612; 50458-563; 50458-611; 50458-562; 50458-608; 50458-607 |
| Synonyms |
Paliperidone Palmitate | Palmitate, Paliperidone | Paliperidone | 9-OH-risperidone | 9 OH risperidone | 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one | 9-Hydroxy-risperidone | 9 Hydroxy risperidone | 9-Hydroxyrisperidone | 9 Hydroxyrisperidone | Invega | Invega Sustenna | Sustenna, Invega | R 76477 | R-76477 | R76477 |
